Vancomycin hydrochloride for Injection &powder

Price: 100.0 USD
Trade Term: FOB,CFR,CIF,DAT,FAS,DDP,DAP,CIP,CPT,FCA,EXW
Payment Terms: T/T,L/C,D/A,D/P,WU,Paypal
skype
Trade on HiSupplier, Worry Free Guarantee
Trading safety, secure your money, lower the risk, protect both buyers and suppliers
HiSupplier is a Chinese multinational company in U.S, it helps to coordination and order landing.
More ›
  • Product Details
  • Company Profile
  • Product Reviews
Basic Info.
  • Product Name: Vancomycin hydrochloride 
  • Synonyms: Vancomycin HCl 
  • CAS No: 1404-93-9 
  • EINECS No: 215-772-6 
  • Molecular Formula: C66H76Cl3N9O24 
  • Molecular Weight: 1485.71 
  • Melting point: above 190°C (dec.) 
  • Appearance: white or almost white crystalline powder 
  • Standard: Enterprise Standard 
  • Packing: 25KG/Drum or as per your requirements 
  • Model No.: 0010 
  • Place of Origin: Hubei  
  • Min.Order: 10 Gram
  • Means of Transport: Land, Ocean, Air
Supply Capacity
  • Production Capacity: 50TON
  • Packing:25KG/Drum or as per your requirements
  • Delivery Date: 15

Vancomycin inhibits growth of many Gram positive bacteria including the antibiotic resistant superbug, MRSA (Methicillin resistant Staphylococcus aureus). Vancomcyin is effective for treating MRSA infections because it inhibits cell wall synthesis through a different mechanism than β-lactam antibiotics.

Product Name: Vancomycin hydrochloride

Synonyms: Vancomycin HCl; Vancomycin monohydrochloride; Vancor; UNII-71WO621TJD; Vancocine hydrochloride; Vancocin hydrochloride;;Lyphocin;Meek;Vancocinehydrochloride;Vancocyn;Vancor;;Meek;VANCOR;VANCOCIN;LYPHOCIN;Vancocyn;VANCOMYCIN HCL;VancoMycin HC1;ycin hydrochloride;vancocinehydrochloride;VANCOCIN HYDROCHLORIDE;;

CAS No.: 1404-93-9

EINECS No.: 215-772-6

Molecular Formula: C66H76Cl3N9O24

Molecular Weight: 1485.71

Melting point: above 190°C (dec.)

Appearance: white or almost white crystalline powder

Standard: Enterprise Standard

Packing: 25KG/Drum or as per your requirements

Application: applied to treatment of pneumonia,endocarditis,sepsis

Vancomycin Hydrochloride for injection, USP is a tricyclic glycopeptide antibiotic derived from Amycolatopasis orientalis(formerly Nocardia orientalis). The chemical name for Vancomycin Hydrochloride is (Sa)-(3S,6R,7R,22R,23S,26S,36R,38aR)-44-[[2-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-α-l-lyxo - hexopyranosyl) - ß - d - glucopyranosyl]oxy] - 3 - (carbamoylmethyl) - 10,19 - dichloro - 2,3,4,5,6,7,23,24,25,26,36,37,38,38a - tetradecahydro - 7,22,28,30,32 - pentahydroxy - 6 - [(2R)-4-methyl-2-(methylamino)]valeramido]-2,5,24,38, 39-pentaoxo-22H-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1H,16H-[1,6,9]oxadiazacyclohexadecino [4,5m][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid, monohydrochloride. The molecular formula is C66H75Cl2N9O24 • HCl and the molecular weight is 1485.71. Vancomycin Hydrochloride has the following structural formula:

Vancomycin Hydrochloride - Clinical Pharmacology

Vancomycin is poorly absorbed after oral administration.

In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mcg/mL immediately after the completion of infusion, mean plasma concentrations of approximately 23 mcg/mL 2 hours after infusion, and mean plasma concentrations of approximately 8 mcg/mL 11 hours after the end of the infusion. Multiple dosing of 500 mg infused over 30 minutes produces mean plasma concentrations of about 49 mcg/mL at the completion of infusion, mean plasma concentrations of about 19 mcg/mL 2 hours after infusion, and mean plasma concentrations of about 10 mcg/mL 6 hours after infusion. The plasma concentrations during multiple dosing are similar to those after a single dose.

The mean elimination half-life of vancomycin from plasma is 4 to 6 hours in subjects with normal renal function. In the first 24 hours, about 75% of an administered dose of vancomycin is excreted in urine by glomerular filtration. Mean plasma clearance is about 0.058 L/kg/hr, and mean renal clearance is about 0.048 L/kg/hr. Renal dysfunction slows excretion of vancomycin. In anephric patients, the average half-life of elimination is 7.5 days. The distribution coefficient is from 0.3 to 0.43 L/kg. There is no apparent metabolism of the drug. About 60% of an intraperitoneal dose of vancomycin administered during peritoneal dialysis is absorbed systemically in 6 hours. Serum concentrations of about 10 mcg/mL are achieved by intraperitoneal injection of 30 mg/kg of vancomycin. However, the safety and efficacy of the intraperitoneal use of vancomycin has not been established in adequate and well-controlled trials (see PRECAUTIONS).

Total systemic and renal clearance of vancomycin may be reduced in the elderly.

Vancomycin is approximately 55% serum protein bound as measured by ultrafiltration at vancomycin serum concentrations of 10 to 100 mcg/mL. After IV administration of vancomycin, inhibitory concentrations are present in pleural, pericardial, ascitic, and synovial fluids; in urine; in peritoneal dialysis fluid; and in atrial appendage tissue. Vancomycin does not readily diffuse across normal meninges into the spinal fluid; but, when the meninges are inflamed, penetration into the spinal fluid occurs.

Microbiology:

The bactericidal action of vancomycin results primarily from inhibition of cell-wall biosynthesis. In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis. There is no cross-resistance between vancomycin and other antibiotics. Vancomycin is not active in vitro against gram-negative bacilli, mycobacteria, or fungi.

Synergy:

The combination of vancomycin and an aminoglycoside acts synergistically in vitro against many strains ofStaphylococcus aureus, Streptococcus bovis, enterococci, and the viridans group streptococci.

Vancomycin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.

Aerobic gram-positive microorganisms

Diphtheroids
Enterococci (e.g., Enterococcus faecalis)
Staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains)
Streptococcus bovis
Viridans group streptococci

The following in vitro data are available, but their clinical significance is unknown.

Vancomycin exhibits in vitro MIC's of 1 mcg/mL or less against most (≥90%) strains of streptococci listed below and MIC's of 4 mcg/mL or less against most (≥90%) strains of other listed microorganisms; however, the safety and effectiveness of vancomycin in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.



Send message to this supplier
Ms. Jason
Tel: 86-27-88211875
Mobile: 18872220774
Enter between 20 to 3,000 chatacters.
Contact Method
Wuhan Yuancheng Gongchuang Technology Co,ltd
#426,Zhongshan Road,Wuchang District, Wuhan, Hubei, China (Mainland) / 430064
Didn't find what you're looking for? Post Buying Lead or contact our customer service specialist for help!
Buyer Help Center